PCA
IMUX icon

Providence Capital Advisors’s Immunic IMUX Stock Holding History

Providence Capital Advisors’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.5K Buy
+682
New +$8.41K ﹤0.01% 281

Other funds holding IMUX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Providence Capital Advisors's IMUX Position: Q2 2026 in Review

Providence Capital Advisors opened a new position in Immunic (IMUX) in Q2 2026: 682 shares worth $10.5K. The stake represents ﹤0.01% of the portfolio and ranks #281 among its holdings.

55 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.

  • Providence Capital Advisors held 682 shares of Immunic worth $10.5K as of Q2 2026.
  • Immunic was a new Providence Capital Advisors position in Q2 2026.
  • Immunic made up ﹤0.01% of Providence Capital Advisors's portfolio in Q2 2026, its #281 holding.
  • 55 funds tracked by Wall St. Rank held Immunic as of Q2 2026.

Based on Providence Capital Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.